Antigen responses were attenuated after ocrelizumab.
Because anti-CD20 monoclonal therapies deplete circulating B cells, they might affect antibody response to new antigen. For this industry-sponsored, multicenter study, investigators enrolled 102 patients with relapsing forms of MS (RMS) who had previous tetanus toxoid (TT) containing vaccination. Participants were randomized to remain on current treatment regimen of either interferon (IFN) or no disease-modifying therapy with plan to switch to ocrelizumab (OCR) after 12 weeks, or to immediately switch to ocrelizumab (OCR). Participants were vaccinated with TT (week 1), neoantigen (KLH; weeks 1, 4, and 8), and 23-valent pneumococcal vaccines (23-PPV; week 4). In addition, patients could receive either seasonal influenza vaccine (INF; either …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)